Abstract:Despite major progress in treating hematologic malignancies and, to a lesser extent, metastatic solid tumors, much work remains ahead. With the anticancer potential of immunotherapy not yet fully exploited, patients with leukemia, malignant lymphoma, and other hematologic malignancies for which high-dose chemoradiotherapy is frequently recommended in conjunction with stem cell transplantation (SCT) can now benefit from the advantages of immunotherapy mediated by cytokines or alloreactive donor lymphocytes, while minimizing procedure-related toxicity and mortality. The feasibility of applying allogeneic cell-mediated immunotherapy in conjunction with allogeneic SCT following reduced-intensity conditioning, with minimal toxicity and no serious transplant-related complications, makes it possible to undertake such procedures on an outpatient basis as well as to offer an option for cure to elderly individuals and patients with less than optimal performance status. Being well tolerated, reduced-intensity transplants also offer a chance for cure to patients with otherwise resistant leukemia and malignant lymphoma who have relapsed after autologous SCT. Thus, the traditional obstacle of very high transplant-related toxicity and mortality due to multiorgan failure from cumulative toxicity of multiple anticancer agents and radiation therapy is overcome. Although immunotherapy mediated by allogeneic lymphocytes can be most effective, the immune potential of donor lymphocytes should be maximized by nonspecific or specific activation in vitro or in vivo, or both, for more effective eradication of resistant tumor cells, including in patients with bulky disease. More important is the challenge to target donor lymphocytes to the tumor and minimize their capacity to induce responses against normal host tissues, which frequently results in severe acute and chronic graft-versus-host disease (GVHD). Alternatively, donor lymphocytes should be eliminated as soon as tumor eradication is completed, or as soon as severe GVHD becomes prohibitive. Based on available experience, clinical application of innovative therapy, especially at the stage of minimal residual disease (MRD), may open new horizons for the treatment of malignancies considered until recently to be incurable. The feasibility of controlling cancer by targeted chemotherapy, best illustrated by the phenomenal activity of imatinib in patients with chronic myelogenous leukemia and, more recently, in gastrointestinal stromal tumors (including in patients fully resistant to all known anticancer agents) suggests that in the future, tumor-specific chemotherapy may represent the ultimate goal for achieving a stage of MRD with minimal multiorgan toxicity. Together, the combination of immunotherapy and targeted chemotherapy may provide the most logical approach for making real progress in controlling resistant hematologic malignancies and metastatic solid tumors.

Aims of conditioning

Antibody based conditioning for allogeneic hematopoietic stem cell transplantation

Maintain Efficacy and Spare Toxicity: Traditional and New Radiation-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside

Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation

The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee

Total Body Irradiation–Based Conditioning Regimen Improved the Survival of Adult Patients with T-Cell Lymphoblastic Lymphoma after Allogeneic Peripheral Blood Stem Cell Transplantation

Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants?

Preconditioning is an Effective Strategy for Improving the Efficiency of Mesenchymal Stem Cells in Kidney Transplantation

[Therapeutic Effect of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimens on Hematological Malignancies].

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy

The progress in preconditioning regimens in allogeneic HSCT

Preconditioning Stem Cells for In Vivo Delivery

Prophylactic or pre-emptive therapies to prevent relapse after allogeneic hematopoietic stem cell transplantation

Basic and clinical studies of non-myeloablative allogeneic hematopoietic stem cell transplantation

Vascular Endothelium Changes after Conditioning in Hematopoietic Stem Cell Transplantation: Role of Cyclophosphamide and Busulfan

Conditioning Regimen with or Without Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Ieukemia

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

Extracellular release of damaged mitochondria induced by pre-hematopoietic stem cell transplant conditioning exacerbates graft-versus-host disease

Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation

Priming of the Cells: Hypoxic Preconditioning for Stem Cell Therapy